Wealth Preservation Advisors’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
Wealth Preservation Advisors's TRDA Position: Q2 2026 in Review
Wealth Preservation Advisors sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 22 shares — an estimated $278 sold.
Wealth Preservation Advisors first reported a position in TRDA in Q1 2026 and held it in 1 quarter. The position peaked at $278 in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.
- Wealth Preservation Advisors reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
- Wealth Preservation Advisors sold 22 Entrada Therapeutics shares in Q2 2026, an estimated $278.
- Wealth Preservation Advisors first reported a position in Entrada Therapeutics in Q1 2026 and held it in 1 quarter.
- Wealth Preservation Advisors's Entrada Therapeutics position peaked at $278 in Q1 2026.
- 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.
Based on Wealth Preservation Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.